TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6111126
Drug: Triazolam (Halcion)
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triazolam (Halcion) 0.25 mg
Study: 26479162
Drug: Oxycodone/Acetaminophen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/Acetaminophen (5 mg/325 mg)
Study: 26176973
Drug: Codeine/Acetaminophen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine/Acetaminophen (30 mg/300 mg)
Study: 21787184
Drug: Mannitol (MTL)
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol (MTL) 20% (4 mL/kg)
Study: 21787184
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (HTS) 7.5% (2 mL/kg)
Study: 17592080
Drug: L-arginine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (3 g/d)
Study: 15106410
Drug: omeprasol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprasol (40 mg/day) and de‐nol (480 mg/day)
Study: 15106410
Drug: omeprasol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprasol (40 mg/day)
Study: 9613647
Drug: Intranasally administered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally administered immunoglobulin (mainly immunoglobulin A), nasal spray, twice daily for 8 weeks
Study: 26473751
Drug: VX-509 100
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-509 100 mg/day
Study: 26473751
Drug: VX-509 200
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-509 200 mg/day
Study: 24196971
Drug: TENS and
Normalized name: ECAMSULE 39.6 mg in 1 mL / OCTINOXATE 67.4 mg in 1 mL / TITANIUM DIOXIDE 32.8 mg in 1 mL TOPICAL CREAM [KIEHLS ULTRA LIGHT DAILY UV DEFENSE TONE UP SPF 50 ANTI POLLUTION INSTANTLY BRIGHTENS AND HYDRATES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS and local injection of cobalamin
Study: 24196971
Drug: TENS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS with a combination of cobalamin and lidocaine
Study: 24196971
Drug: TENS and
Normalized name: ECAMSULE 39.6 mg in 1 mL / OCTINOXATE 67.4 mg in 1 mL / TITANIUM DIOXIDE 32.8 mg in 1 mL TOPICAL CREAM [KIEHLS ULTRA LIGHT DAILY UV DEFENSE TONE UP SPF 50 ANTI POLLUTION INSTANTLY BRIGHTENS AND HYDRATES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS and local injection of lidocaine
Study: 16417774
Drug: Suogudan Granule
Normalized name: REHMANNIA GLUTINOSA WHOLE 3 g ORAL TABLET [SUODAN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suogudan Granule (SGDG) 6 g orally, thrice a day for 6 weeks
Study: 1923078
Drug: Amoxicillin‐potassium clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐potassium clavulanate
Study: 25733639
Drug: High flavanol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flavanol (HF) cocoa flavanols (993 mg)
Study: 25733639
Drug: Intermediate flavanol
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate flavanol (IF) cocoa flavanols (520 mg)
Study: 25733639
Drug: Low flavanol
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flavanol (LF) cocoa flavanols (48 mg)
Study: 24393375
Drug: FAIM2-rs7138803 polymorphism
Normalized name: ANGELICA POLYMORPHA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAIM2-rs7138803 polymorphism (AA vs G-carriers)
Study: 24393375
Drug: FAIM2-rs7138803 polymorphism
Normalized name: ANGELICA POLYMORPHA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAIM2-rs7138803 polymorphism (AA vs G-carriers) in type-2 diabetic subjects
Study: 2104036
Drug: Diet 1
Normalized name: Phendiet 105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 1 (D1, n = 5) - 450‐550 kcal/d, protein at 1.5 g/kg IBW, less than 10 g carbohydrate (CHO)
Study: 2104036
Drug: Diet 2
Normalized name: gluc-msm-vit C-FA-mang-diet 29 125 mg-37.5 mg-25 mg-500 mcg-1.25 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 2 (D2, n = 5) - 420 kcal/d formula, providing 70 g (1.2 g/kg IBW) protein and 30 g CHO
Study: 7467379
Drug: Droperidol (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (higher dosage)
Study: 17227743
Drug: Homeopathic Arnica
Normalized name: ARNICA MONTANA WHOLE 6 [hp_X] ORAL LOZENGE [Homeopathic Arnica Drops]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic Arnica 30c, 2 tablets 6 times on the first post-operative day and then 2 tablets twice a day for the next 7 days
Study: 17227743
Drug: Identical placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo, 2 tablets 6 times on the first post-operative day and then 2 tablets twice a day for the next 7 days
Study: 15155712
Drug: VIP at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP at doses ranging from 25 to 800 pmol
Study: 15155712
Drug: Inhibition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibition of H1 receptors
Study: 15155712
Drug: Combined H1‐receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined H1‐receptor inhibition and NO synthase inhibition
Study: 15155712
Drug: H2‐receptor inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2‐receptor inhibition
Study: 2609672
Drug: Intravenous Doxepin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Doxepin treatment
Study: 2609672
Drug: Oral Doxepin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Doxepin treatment
Study: 26483357
Drug: Dronabinol 10
Normalized name: dronabinol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol 10 mg
Study: 23684127
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning methodology using pre-treatment EEG data for predicting response to SSRI treatment
Study: 21275593
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment coverage (80%-90%)
Study: 21275593
Drug: High treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High treatment coverage (over 90%)
Study: 21275593
Drug: Annual treatment
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual treatment for 3 years
Study: 21275593
Drug: Graduation rule
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graduation rule (halt treatment based on absence of follicular trachoma or infection)
Study: 19783552
Drug: Weekly gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly gemcitabine (1000 mg/m²) and split-dose cisplatin (40 mg/m²) administered on days 1 and 8 at 3-week intervals for four cycles.
Study: 19783552
Drug: Weekly gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly gemcitabine and split-dose cisplatin
Study: 16571153
Drug: Tomatoes, tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomatoes, tomato juice, tomato purée (12.5 mg lycopene/d for 4 weeks)
Study: 24178584
Drug: Classroom-centered (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classroom-centered (CC) intervention
Study: 8739513
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (300 micrograms and 600 micrograms per day by nasal spray for 6 months)
Study: 2017313
Drug: defibrotide 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: defibrotide 400 mg b.i.d. IM (starting the day before surgery and continuing for the following 7 days)
Study: 29077924
Drug: Perioperative Behavioral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative Behavioral Therapy (BPMT)
Study: 17437654
Drug: Dexamethasone 0.5
Normalized name: dexamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg kg‐1
Study: 9512946
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch (HES) 200 ml/l of ascites removed, n = 27
Study: 7527326
Drug: Quinapril 10
Normalized name: quinapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 10 to 40 mg/day
Study: 30691753
Drug: Combined exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined exercise therapy (closed kinetic chain exercises and proprioception exercises)
Study: 26761968
Drug: Thiotriazoline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiotriazoline (600 mg/d)
Study: 26761968
Drug: Trimetazidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (60 mg/d)
Study: 17592240
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone (IVT) 4 mg
Study: 12900738
Drug: Metoprolol (MET),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (MET), 50 mg
Study: 12900738
Drug: Amlodipine (AML),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (AML), 5 mg
Study: 10847214
Drug: Computerized self‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized self‐administered interview
Study: 8415401
Drug: Buffered solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered solution of didanosine
Study: 8415401
Drug: Chewable tablet
Normalized name: Chewable Tablet
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable tablet and antacid suspension
Study: 8415401
Drug: Buffered solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered solution of didanosine in humans
Study: 22290044
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) injections
Study: 22457293
Drug: 23vP (23-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23vP (23-valent unconjugated pneumococcal polysaccharide vaccine)
Study: 15910869
Drug: Atorvastatin 10mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 10mg
Study: 16292115
Drug: Case management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case management plus treatment as usual
Study: 25024314
Drug: ABT-288 3
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-288 3 mg
Study: 20140523
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy with recombinant human arylsulfatase B (rhASB) at 1 mg/kg weekly for up to 240 weeks
Study: 18762755
Drug: Neuroprotective agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroprotective agents
Study: 8858268
Drug: Cilazapril 0.5
Normalized name: cilazapril 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 0.5 mg daily
Study: 1298871
Drug: 5-hydroxytryptophan (OH-TRY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxytryptophan (OH-TRY) 500 mg
Study: 720003
Drug: Propranolol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (single dose)
Study: 6370283
Drug: Metoprolol (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (chronic treatment)
Study: 25139469
Drug: Correction methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correction methods applied to Women's Health Initiative hormone therapy trials
Study: 21728788
Drug: Weighted balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weighted balloon catheter with 1000 mL fluid bag
Study: 19097106
Drug: 0.1 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mmol/kg contrast agent
Study: 19097106
Drug: 0.2 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mmol/kg contrast agent
Study: 10720857
Drug: Alfuzosin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 2.5 mg thrice daily
Study: 1422291
Drug: Xylocaine spray
Normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylocaine spray with frigen, two applications (20 mg lidocaine)
Study: 1422291
Drug: Xylestesin spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylestesin spray with frigen, two applications (14 mg lidocaine)
Study: 1422291
Drug: Xylestesin spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylestesin spray with frigen, three applications (21 mg lidocaine)
Study: 1422291
Drug: Xylestesin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylestesin pump spray without frigen, two applications (14 mg lidocaine)
Study: 1392679
Drug: no topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: no topical anesthesia
Study: 30973547
Drug: +NENS (nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: +NENS (nutrition education and nutrition supplements)
Study: 30973547
Drug: +NS (nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: +NS (nutrition supplements)
Study: 30973547
Drug: +NS (nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: +NS (nutrition supplements) and +NENS (nutrition education and nutrition supplements)
Study: 26687921
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both (CI)
Study: 23135690
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 10 mL/kg‐1 at a rate of 10 breaths/minute (Group 10)
Study: 23135690
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 5 mL/kg‐1 with 5 cmH2O PEEP at a rate of 20 breaths/minute (Group 5)
Study: 2221490
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g vitamin C
Study: 16368837
Drug: Sitting position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitting position during initiation of small-dose combined spinal-epidural anesthesia (CSE)
Study: 16368837
Drug: Lateral position
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral position during initiation of small-dose combined spinal-epidural anesthesia (CSE)
Study: 11004326
Drug: Continuous ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous ceftazidime infusion
Study: 1451928
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation
Study: 3711028
Drug: Haloperidol (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (1, 2, and 5 mg/day for 2 weeks)
Study: 29763659
Drug: BGF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF MDI 160/14.4/10 μg and BGF MDI 320/14.4/10 μg
Study: 19671948
Drug: Positive anti-TPO
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive anti-TPO antibodies
Study: 20057257
Drug: Community-based medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based medication reconciliation (CMR) system, involving a clinical pharmacist visiting patients' homes within 72 hours of hospital discharge.
Study: 20057257
Drug: Community-based medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based medication reconciliation (CMR) system
Study: 15928790
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation and work therapy
Study: 11764012
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg (placebo)
Study: 12095665
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of oral cocaine HCl
Study: 12095665
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of oral cocaine HCl
Study: 29901753
Drug: 1000 µg
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 µg folic acid daily (as part of a multivitamin) throughout pregnancy and lactation until 8 weeks postpartum
Study: 10513865
Drug: Ondansetron (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (2.0 mL = 4.0 mg)
Study: 7725371
Drug: Systematic approach
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic approach to individualizing phenytoin dose based on one-point, steady-state plasma concentration
Study: 6156412
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g i.v. gammaglobulin (Intraglobin)
Study: 12582353
Drug: Cancellous cores
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancellous cores (CC) harvested through a 0.5- to 1.0-cm incision with a motor-driven trephine
Study: 1431009
Drug: Amitriptyline 75
Normalized name: amitriptyline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 75 mg daily in divided doses (increased at week 3 if necessary)
Study: 7652032
Drug: Caffeine 0
Normalized name: caffeine 0.65 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 0 mg/kg
Study: 23121473
Drug: Vildagliptin +
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin + metformin
Study: 18513646
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no BMC treatment)
Study: 15742825
Drug: Caffeine gum
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine gum 0 mg (placebo)
Study: 15742825
Drug: Caffeine gum
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine gum 100 mg (low dose)
Study: 15742825
Drug: Caffeine gum
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine gum 300 mg (high dose)
Study: 12095806
Drug: Trimethoprim (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (160 mg)/sulfamethoxazole (800 mg) every 3 days (61 patients)
Study: 9827404
Drug: Lower than
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower than recommended heparin dosage
Study: 2684551
Drug: Slow-release oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release oral ketotifen
Study: 27824434
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine 266 mg/20 mL (admixed with standard bupivacaine 0.5% 20 mL)
Study: 27824434
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% 20 mL
Study: 22683226
Drug: Controlled-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release carbamazepine 200 mg/day up-titrated to 600 mg/day
Study: 11865962
Drug: Standard intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intramuscular varicella zoster immune globulin (VZIG)
Study: 10526698
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers (lipophilic agents such as timolol, metoprolol, propranolol, bisoprolol, and carvedilol)
Study: 7839425
Drug: Double-drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-drug therapy (azathioprine and prednisolone)
Study: 1610863
Drug: Triple-drug therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug therapy (cyclosporine, azathioprine, and prednisolone)
Study: 7839425
Drug: Triple-drug to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug to double-drug therapy conversion
Study: 2495049
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 mg three times daily for the first month, then 40 mg three times daily thereafter)
Study: 2568785
Drug: Iohexol 300
Normalized name: IOHEXOL 300MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol 300 mg I/ml
Study: 514499
Drug: Conray meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conray meglumine 282 mg I/ml
Study: 7043304
Drug: Amipaque 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amipaque 300 mg I/ml
Study: 30600733
Drug: Histopathology diagnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histopathology diagnosis of collagenous colitis (CC)
Study: 12953084
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium clodronate (2080 mg/day)
Study: 30472902
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release CLM tablets
Study: 23786783
Drug: Methotrexate 20
Normalized name: METHOTREXATE 20MG/0.8ML SOLN INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 20 mg subcutaneously once weekly
Study: 20067113
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no medication before resection)
Study: 10376168
Drug: Diclofenac-potassium 50
Normalized name: Diclofenac Potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac-potassium 50 mg
Study: 10376168
Drug: Diclofenac-potassium 100
Normalized name: Diclofenac Potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac-potassium 100 mg
Study: 6474360
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (continuous infusion after premedication)
Study: 6474360
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (for high-risk patients)
Study: 19379098
Drug: 0.5% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% sodium hypochlorite solution
Study: 30017164
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine gluconate solution
Study: 30017164
Drug: 5% sodium
Normalized name: Dextrose 5% and 0.45% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sodium bicarbonate solution
Study: 18959455
Drug: Live music
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live music therapy sessions (pre and postoperative)
Study: 12840089
Drug: Nebulized epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized epinephrine (1 percent, 4 ml doses)
Study: 12840089
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline, 4 ml doses)
Study: 11197923
Drug: Individual psychosocial
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual psychosocial treatment
Study: 6396120
Drug: Bifonazole cream
Normalized name: bifonazole
DrugBank: Bifonazole (DB04794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole cream applied once or twice daily